Selected research
Market Structure
Global Dystrophin Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Dystrophin market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Dystrophin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Dystrophin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Dystrophin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Dystrophin is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Dystrophin include Pfizer Inc, Daiichi Sankyo Company Ltd, WAVE Life Sciences Ltd, Sarepta Therapeutics Inc, Nippon Shinyaku Co Ltd, Genethon SA, Editas Medicine Inc, BioMarin Pharmaceutical Inc and Asklepios BioPharmaceutical Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Dystrophin market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Dystrophin and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Dystrophin sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Dystrophin market size, projected growth trends, production technologies, key applications, and end-use industries.
Dystrophin Segment by Company
Pfizer Inc
Daiichi Sankyo Company Ltd
WAVE Life Sciences Ltd
Sarepta Therapeutics Inc
Nippon Shinyaku Co Ltd
Genethon SA
Editas Medicine Inc
BioMarin Pharmaceutical Inc
Asklepios BioPharmaceutical Inc
Dystrophin Segment by Type
DS-5141
Biostrophin
BMBD-001
NS-065
Others
Dystrophin Segment by Application
Genetic Disorders
Musculoskeletal Disorders
Others
Dystrophin Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Dystrophin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Dystrophin and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Dystrophin.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Dystrophin market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Dystrophin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Dystrophin in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Dystrophin in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- DS-5141
- Biostrophin
- BMBD-001
- NS-065
- Others
Applications
- Genetic Disorders
- Musculoskeletal Disorders
- Others
Companies covered
- Pfizer Inc
- Daiichi Sankyo Company Ltd
- WAVE Life Sciences Ltd
- Sarepta Therapeutics Inc
- Nippon Shinyaku Co Ltd
- Genethon SA
- Editas Medicine Inc
- BioMarin Pharmaceutical Inc
- Asklepios BioPharmaceutical Inc
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Dystrophin Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Dystrophin Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Dystrophin Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Dystrophin Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Dystrophin Market Dynamics
- 2.1 Dystrophin Industry Trends
- 2.2 Dystrophin Industry Drivers
- 2.3 Dystrophin Industry Opportunities and Challenges
- 2.4 Dystrophin Industry Restraints
3 Dystrophin Market by Manufacturers
- 3.1 Global Dystrophin Revenue by Manufacturers (2021-2026)
- 3.2 Global Dystrophin Sales by Manufacturers (2021-2026)
- 3.3 Global Dystrophin Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Dystrophin Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Dystrophin Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Dystrophin Manufacturers, Product Type & Application
- 3.7 Global Dystrophin Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Dystrophin Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Dystrophin Players Market Share by Revenue in 2025
- 3.8.3 2025 Dystrophin Tier 1, Tier 2, and Tier 3
4 Dystrophin Market by Type
- 4.1 Dystrophin Type Introduction
- 4.1.1 DS-5141
- 4.1.2 Biostrophin
- 4.1.3 BMBD-001
- 4.1.4 NS-065
- 4.1.5 Others
- 4.2 Global Dystrophin Sales by Type
- 4.2.1 Global Dystrophin Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Dystrophin Sales by Type (2021-2032)
- 4.2.3 Global Dystrophin Sales Market Share by Type (2021-2032)
- 4.3 Global Dystrophin Revenue by Type
- 4.3.1 Global Dystrophin Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Dystrophin Revenue by Type (2021-2032)
- 4.3.3 Global Dystrophin Revenue Market Share by Type (2021-2032)
5 Dystrophin Market by Application
- 5.1 Dystrophin Application Introduction
- 5.1.1 Genetic Disorders
- 5.1.2 Musculoskeletal Disorders
- 5.1.3 Others
- 5.2 Global Dystrophin Sales by Application
- 5.2.1 Global Dystrophin Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Dystrophin Sales by Application (2021-2032)
- 5.2.3 Global Dystrophin Sales Market Share by Application (2021-2032)
- 5.3 Global Dystrophin Revenue by Application
- 5.3.1 Global Dystrophin Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Dystrophin Revenue by Application (2021-2032)
- 5.3.3 Global Dystrophin Revenue Market Share by Application (2021-2032)
6 Global Dystrophin Sales by Region
- 6.1 Global Dystrophin Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Dystrophin Sales by Region (2021-2032)
- 6.2.1 Global Dystrophin Sales by Region (2021-2026)
- 6.2.2 Global Dystrophin Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Dystrophin Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Dystrophin Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Dystrophin Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Dystrophin Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Dystrophin Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Dystrophin Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Dystrophin Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Dystrophin Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Dystrophin Revenue by Region
- 7.1 Global Dystrophin Revenue by Region
- 7.1.1 Global Dystrophin Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Dystrophin Revenue by Region (2021-2026)
- 7.1.3 Global Dystrophin Revenue by Region (2027-2032)
- 7.1.4 Global Dystrophin Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Dystrophin Revenue (2021-2032)
- 7.2.2 North America Dystrophin Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Dystrophin Revenue (2021-2032)
- 7.3.2 Europe Dystrophin Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Dystrophin Revenue (2021-2032)
- 7.4.2 Asia-Pacific Dystrophin Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Dystrophin Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Dystrophin Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Pfizer Inc
- 8.1.1 Pfizer Inc Company Information
- 8.1.2 Pfizer Inc Business Overview
- 8.1.3 Pfizer Inc Dystrophin Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Pfizer Inc Dystrophin Product Portfolio
- 8.1.5 Pfizer Inc Recent Developments
- 8.2 Daiichi Sankyo Company Ltd
- 8.2.1 Daiichi Sankyo Company Ltd Company Information
- 8.2.2 Daiichi Sankyo Company Ltd Business Overview
- 8.2.3 Daiichi Sankyo Company Ltd Dystrophin Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Daiichi Sankyo Company Ltd Dystrophin Product Portfolio
- 8.2.5 Daiichi Sankyo Company Ltd Recent Developments
- 8.3 WAVE Life Sciences Ltd
- 8.3.1 WAVE Life Sciences Ltd Company Information
- 8.3.2 WAVE Life Sciences Ltd Business Overview
- 8.3.3 WAVE Life Sciences Ltd Dystrophin Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 WAVE Life Sciences Ltd Dystrophin Product Portfolio
- 8.3.5 WAVE Life Sciences Ltd Recent Developments
- 8.4 Sarepta Therapeutics Inc
- 8.4.1 Sarepta Therapeutics Inc Company Information
- 8.4.2 Sarepta Therapeutics Inc Business Overview
- 8.4.3 Sarepta Therapeutics Inc Dystrophin Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Sarepta Therapeutics Inc Dystrophin Product Portfolio
- 8.4.5 Sarepta Therapeutics Inc Recent Developments
- 8.5 Nippon Shinyaku Co Ltd
- 8.5.1 Nippon Shinyaku Co Ltd Company Information
- 8.5.2 Nippon Shinyaku Co Ltd Business Overview
- 8.5.3 Nippon Shinyaku Co Ltd Dystrophin Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Nippon Shinyaku Co Ltd Dystrophin Product Portfolio
- 8.5.5 Nippon Shinyaku Co Ltd Recent Developments
- 8.6 Genethon SA
- 8.6.1 Genethon SA Company Information
- 8.6.2 Genethon SA Business Overview
- 8.6.3 Genethon SA Dystrophin Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Genethon SA Dystrophin Product Portfolio
- 8.6.5 Genethon SA Recent Developments
- 8.7 Editas Medicine Inc
- 8.7.1 Editas Medicine Inc Company Information
- 8.7.2 Editas Medicine Inc Business Overview
- 8.7.3 Editas Medicine Inc Dystrophin Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Editas Medicine Inc Dystrophin Product Portfolio
- 8.7.5 Editas Medicine Inc Recent Developments
- 8.8 BioMarin Pharmaceutical Inc
- 8.8.1 BioMarin Pharmaceutical Inc Company Information
- 8.8.2 BioMarin Pharmaceutical Inc Business Overview
- 8.8.3 BioMarin Pharmaceutical Inc Dystrophin Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 BioMarin Pharmaceutical Inc Dystrophin Product Portfolio
- 8.8.5 BioMarin Pharmaceutical Inc Recent Developments
- 8.9 Asklepios BioPharmaceutical Inc
- 8.9.1 Asklepios BioPharmaceutical Inc Company Information
- 8.9.2 Asklepios BioPharmaceutical Inc Business Overview
- 8.9.3 Asklepios BioPharmaceutical Inc Dystrophin Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 Asklepios BioPharmaceutical Inc Dystrophin Product Portfolio
- 8.9.5 Asklepios BioPharmaceutical Inc Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Dystrophin Value Chain Analysis
- 9.1.1 Dystrophin Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Dystrophin Production Mode & Process
- 9.2 Dystrophin Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Dystrophin Distributors
- 9.2.3 Dystrophin Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst